InvestSMART

Healius Limited (ASX:HLS)

ALERT: Price-sensitive ASX Announcement for HLS
Current share price for HLS : $0.435 -0.01 (-2.25%)+
Announcement
Release
19 Aug 2026 9:47AM
Price at Release
$0.445
Full Release
download
Summary
In FY26, Healius Limited saw a 2.1% increase in underlying revenue to $1,373.2 million, driven by improved revenue mix in Pathology and significant growth in Agilex Biolabs. The group achieved underlying EBITDA growth of 8.1% to $258.6 million and an underlying EBIT growth of 76.6% to $30.2 million, despite overall reported losses due to non-cash impairment charges. Pathology revenue rose by 1.8%, supported by cost discipline and efficiency initiatives, while Agilex Biolabs reported a 14.1% revenue increase, benefiting from strategic pivots and expansions. Cost-saving measures exceeded targets, achieving $24.4 million in annualised savings. The company remains focused on optimizing its operations, exploring potential sales of Agilex Biolabs, and enhancing its technological capabilities. Healius expects continued growth into FY27, with EBIT projections aligning with market consensus.
Key Points
  • Underlying revenue grew by 2.1% to $1,373.2 million.
  • Significant improvement in Pathology and Agilex Biolabs performance.
  • Achieved annualized cost savings of $24.4 million.
  • Strong growth in Genomics and Clinical Trials.
  • Exploring sale of Agilex Biolabs due to high interest.
  • Continued focus on cost efficiency and revenue quality.
  • Strategic technological advancements and digital transformations completed.
  • Reported significant non-cash impairment charges impacting overall profit.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.